

S 326

VA Medicinal Cannabis Research Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Armed Forces and National Security

Introduced: Feb 9, 2023

Current Status: Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326

Latest Action: Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate. (Apr 26, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/326>

Sponsor

Name: Sen. Tester, Jon [D-MT]

Party: Democratic • State: MT • Chamber: Senate

Cosponsors (9 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Sullivan, Dan [R-AK]	R · AK		Feb 9, 2023
Sen. Duckworth, Tammy [D-IL]	D · IL		Mar 6, 2023
Sen. Fetterman, John [D-PA]	D · PA		Apr 25, 2023
Sen. Hickenlooper, John W. [D-CO]	D · CO		Apr 25, 2023
Sen. Kelly, Mark [D-AZ]	D · AZ		Apr 25, 2023
Sen. King, Angus S., Jr. [I-ME]	I · ME		Apr 25, 2023
Sen. Rosen, Jacky [D-NV]	D · NV		Apr 25, 2023
Sen. Sinema, Kyrsten [I-AZ]	I · AZ		Apr 25, 2023
Sen. Young, Todd [R-IN]	R · IN		Apr 25, 2023

Committee Activity

Committee	Chamber	Activity	Date
Veterans' Affairs Committee	Senate	Reported By	Mar 23, 2023

Subjects & Policy Tags

Policy Area:

Armed Forces and National Security

Related Bills

Bill	Relationship	Last Action
118 HR 1003	Identical bill	Mar 13, 2023: Referred to the Subcommittee on Health.

VA Medicinal Cannabis Research Act of 2023

This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans).

First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials.

Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants.

The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants.

The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census.

The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).

Actions Timeline

- **Apr 26, 2023:** Cloture on the motion to proceed to the measure not invoked in Senate by Yea-Nay Vote. 57 - 42. Record Vote Number: 97.
- **Apr 26, 2023:** Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.
- **Apr 20, 2023:** Motion to proceed to consideration of measure made in Senate.
- **Apr 20, 2023:** Cloture motion on the motion to proceed to the measure presented in Senate. (CR S1286)
- **Mar 23, 2023:** Committee on Veterans' Affairs. Reported by Senator Tester without amendment. Without written report.
- **Mar 23, 2023:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 32.
- **Feb 16, 2023:** Committee on Veterans' Affairs. Ordered to be reported without amendment favorably.
- **Feb 9, 2023:** Introduced in Senate
- **Feb 9, 2023:** Read twice and referred to the Committee on Veterans' Affairs.